Promegestone: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Promegestone.svg|Promegestone | |||
File:Trimegestone.svg|Trimegestone | |||
</gallery> | |||
Latest revision as of 01:56, 17 February 2025
Promegestone (R-5020) is a synthetic, steroidal progestin that is used in menopausal hormone therapy and for other indications. It is marketed solely in France under the brand name Surgestone for the treatment of conditions like menopausal symptoms, gynecological disorders, and breast cancer.
Pharmacology[edit]
Promegestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has strong progestogenic effects and weak antiandrogen and glucocorticoid effects.
Medical uses[edit]
Promegestone is used in menopausal hormone therapy, for gynecological disorders such as abnormal uterine bleeding, and in the treatment of breast cancer.
Side effects[edit]
The side effects of promegestone are similar to those of other progestins. They can include menstrual irregularities, headache, nausea, breast tenderness, mood changes, acne, increased hair growth, and others.
Chemistry[edit]
Promegestone, also known as 17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone and 19-norprogesterone.
History[edit]
Promegestone was developed by Roussel Uclaf and was introduced for medical use by 1983.


